000			a
999			_c11251 _d11251
003			OSt
005			20200214110603.0
008			200214b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_912256 _aAbobakr, Fatma E.
245			_aFORMULATION AND OPTIMIZATION OF TERBINAFINE HCl SOLID LIPID NANOPARTICLES FOR TOPICAL ANTIFUNGAL ACTIVITY
250			_aVol.11(12)
260			_aM P _bInnovare Academic Sciences Pvt Ltd _c2019
300			_a16-25p.
520			_aObjective: Soli d lipid nanoparticles (SLNs) are at the forefront of the rapidly developing field of nanotechnology with several potential applications in drug delivery and res earch. The aim of this study was to develop and characterize SLNs formulae of Terbinafine HCl (TFH) for topical drug delivery application s. Method s: SLNs were prepared using the solvent injection technique. Glyceryl M onostearate (GMS) served as the lipid base. Three stabilizer s; Tween 80, C remophor RH40 , and Poloxame r 188 , were used. The effect of stabilizer type and concentration , as well as the li pid concentration , were studied , factorial design of 3 2 *2 1 was applied. The prepared SLNs were characterized regarding their particle size, zeta potential, polydispersity index (PDI) , entrapment eff iciency percent (EE %) , and physicochemical stability. The selected formulae were subjected to further investigations such as morphological studies, in vitro release studies , and Infrared (IR) spectroscopy. The y were compared with the marketed cream Lamifen ® in term of their antifungal activity against Candida alb icans . Result s: Lipid concentration , together with the type and concentration of stabilizer , appeared to be the main cornerstones which affect the formation of SLNs. Smaller particle size was observed when increasing the stabilizer concentration and decrea sing the lipid concentration. Higher EE% was observed when increasing both the stabilizer and the lipid concentration s. Formulae (F6, F12 andF19) were selected as the most suitable SLNs with optimum particle size of 480.2 ±18.89, 458.6 ±12.45 and 246.7 ±10.5 nm , respectively as well as the highest EE% of 87.13 ±0.19, 93.69 ±0.7 and 95.06 ±0.25 , respectivel y. In vitro microbiological screening of their antifungal activity showed significantly larger zone s of inhibition of diameters 25.9 ±0.25, 25 ±0.35 and 24.67 ±0.3 6 mm , respectively in comparison with the marketed Lamifen® cream which showed a zone of 11.2 ±0.44 mm diameter . Conclusio n: Applying SLNs containing TFH as topic
650		0	_94639 _aPHARMACEUTICS
700			_912257 _aSahar, M. Fayez
773	0		_tInternational journal of pharmacy and pharmaceutical science _dBhopal Innovare Academic Sciences Pvt Ltd _x2656-0097
856			_uhttps://innovareacademics.in/journals/index.php/ijpps/article/view/35560/21240 _yClick here
942			_2ddc _cAR